Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study

SIMPLE SUMMARY: Atezolizumab plus bevacizumab (Atez/Bev) is the first-line treatment for unresectable advanced hepatocellular carcinoma (HCC). The tumor markers (TMs) for HCC include alpha-fetoprotein (AFP), fucosylated alpha-fetoprotein (AFP-L3), and des-gamma carboxyprothrombin (DCP). A TM score c...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Kazunari, Tsuji, Kunihiko, Hiraoka, Atsushi, Tada, Toshifumi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Naganuma, Atsushi, Kosaka, Hisashi, Matono, Tomomitsu, Kuroda, Hidekatsu, Yata, Yutaka, Ohama, Hideko, Tada, Fujimasa, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Yokohama, Keisuke, Nishikawa, Hiroki, Imai, Michitaka, Koizumi, Yohei, Nakamura, Shinichiro, Iijima, Hiroko, Kaibori, Masaki, Hiasa, Yoichi, Kumada, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486534/
https://www.ncbi.nlm.nih.gov/pubmed/37686624
http://dx.doi.org/10.3390/cancers15174348

Ejemplares similares

Ejemplares similares